Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Gilead Japan Hooks Up with Arthritis-Savvy Eisai for JAK Inhibitor
December 25, 2019
- ASKA Files Uterine Fibroid Drug in Japan
December 25, 2019
- Renascience, ASKA Pair Up to Develop Pyridoxamine
December 25, 2019
- Sosei, Pfizer Nominate 3rd Development Candidate Compound
December 25, 2019
- Towa to Acquire Spanish Generic Player, Set to Venture into US/European Markets
December 24, 2019
- Eisai’s Insomnia Drug Grabs US Approval, Japan Nod Expected Soon
December 24, 2019
- US FDA Accepts Resubmission for Sunovion’s Parkinson’s Med
December 24, 2019
- Promethera to Launch Japan Trial of Cell Therapy Targeting ACLF by FY2021
December 24, 2019
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
December 23, 2019
- Bayer, Santen Extend Eylea Tie-Up in Japan
December 23, 2019
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
- Takahiko Iwaya to Take Over as Sanofi Japan President on Jan. 1
December 20, 2019
- Takecab Back on Top in Hospital Promotion Ranking in October: Impact Track
December 19, 2019
- Biogen Eyes 2020 Aducanumab Filing in Japan Too, Nailing Down Re-Dosing Study Details
December 19, 2019
- Jardiance Delivers Favorable Data in Asian RWD Analysis: Boehringer/Lilly
December 19, 2019
- Daiichi Sankyo Aims to Become Global Leader of ADCs: CEO
December 18, 2019
- Chugai Names EVP Okuda as New President
December 18, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…